Chemomab Therapeutics (CMMB) Change in Accured Expenses (2019 - 2023)

Chemomab Therapeutics (CMMB) has 5 years of Change in Accured Expenses data on file, last reported at -$366000.0 in Q4 2023.

• Quarterly Change in Accured Expenses fell 145.69% year-over-year to -$366000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$737000.0 (down 126.11% YoY) and the FY2025 annual result came in at -$1.2 million, up 36.3% from the prior year.
• Change in Accured Expenses eased to -$366000.0 in Q4 2023, from $504000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $922000.0 in Q4 2019 to a low of -$1.1 million in Q2 2021.
• A 5-year average of $75000.0 and a median of -$33500.0 in 2020 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2021 — Change in Accured Expenses slumped 2100.0% — and 2022, when it jumped 4550.0%.
• Tracing CMMB's Change in Accured Expenses over 5 years: stood at $922000.0 in 2019, then tumbled by 71.69% to $261000.0 in 2020, then sank by 106.9% to -$18000.0 in 2021, then jumped by 4550.0% to $801000.0 in 2022, then plunged by 145.69% to -$366000.0 in 2023.
• The last three Change in Accured Expenses figures came in at -$366000.0 (Q4 2023), $504000.0 (Q3 2023), and -$661000.0 (Q2 2023), per Business Quant data.